ObjectiveTo explore the status of common comorbidities in adult epilepsy patients in western China, and to explore the related risk factors.MethodsThe Chinese version of Generalized Anxiety Disorder (GAD)-7, neurological disorders depression inventory for epilepsy (NDDI-E) scales, pittsburgh sleep quality index scale (PSQI) and epworth sleepiness scale (ESS) were used to evaluate the 199 epilepsy patients between April 2017 and March 2018 in the Epilepsy Center of Neurology Department of Sichuan People's Hospital. Logistic regression analysis was performed on the risk factors of epilepsy comorbidity.ResultsIn the 199 adult epilepsy patients, 28.1% had anxiety, 17.1% had depression, 33.2% had sleep disorder, and 2.5% had migraine. 140 patients received monotherapy, including 15 patients with carbamazepine (CBZ), 20 patients with lamotrigine (LTG), 26 patients with levetiracetam (LEV), 31 patients with topiramate (TPM), 25 patients with oxcarbazepine (OXC), and 23 patients with Valproate (VPA).Multivariate logistic regression analysis of epilepsy patients treated with monotherapy showed that seizure occurring more than once a month, LEV, TPM, sleep disorders were independent risk factors for anxiety in patients with epilepsy (P<0.05). Unemployment, seizure occurrence in the last three months, sleep disorders were independent risk factors for comorbid depression (P<0.05). Anxiety, depression, daytime sleepiness, CBZ, LTG were independent risk factors for comorbid sleep disorders (P<0.05).ConclusionsAnxiety, depression and sleep disorder are common comorbidities in adults with epilepsy in westChina. For patients with affective disorder and sleep disorder, early identification and intervention may be important to improve the quality of life and prognosis of patients. In addition, patients treated with LEV or TPM monotherapy had a higher risk of anxiety than other drugs. Patients with LTG and CBZ monotherapy are more likely to comorbid sleep disorders.
ObjectivesTo systematically review the epidemiological characteristics of post-stroke shoulder pain (PSSP).MethodsPubMed, WanFang Data, CNKI, EMbase, The Cochrane Library and SinoMed databases were electronically searched to collect studies on the morbidity of PSSP from inception to November 30th, 2019. Two reviewers independently screened literature, extracted data and assessed risk of bias of included studies, then, meta-analysis was performed by using Stata 15.0 software.ResultsA total of 13 studies were included. The total sample size was 3 514, including 1 357 patients with PSSP. The results of meta-analysis showed that the total morbidity of PSSP was 45.0% with 95%CI 32.0% to 58.0%. The results of subgroup analysis showed that the morbidity of PSSP was 55.5% (95%CI 48.1% to 63.0%) prior to 2010 and 40.6% (95%CI 28.3% to 52.9%) after 2010, respectively. The morbidity of PSSP in Asia was 61.2% (95%CI 51.3% to 71.1%), and in Europe and America was 18.4% (95%CI 9.9% to 26.9%), respectively.ConclusionsCurrent evidence suggests that PSSP has high morbidity, and it may be affected by regional factors. Due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions.
